NABATIVI intends to translate basic research into clinical applications in the area of antimicrobial drug resistance. NABATIVI aims to identify novel drugs against multi-resistant P. aeruginosa and B. cenocepacia with sufficient potential for further preclinical development. The development and validation of new therapies fostered by NABATIVI results are expected to impact on health promotion and prevention as well as to contribute significantly to the sustainability of efficient health care systems.